illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Novacyts
Company logo

Novacyts | Sustainability Performance

https://novacyt.com/

Develops molecular diagnostic products and testing solutions, with platforms designed for clinical and laboratory applications. It operates across research, development, and commercialization stages of diagnostic technologies.

2006

United Kingdom

201 - 500 employees

Biotechnology

$25M - 100M in revenue

Not profitable

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#6654
Overall
#933
in United Kingdom
#129
in Biotechnology

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

213 out of 245

Overview
Governance
TargetsESG scores and Exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
Clinigen

United Kingdom, Health Care, Pharmaceuticals


Company logo
Smith & Nephew

United Kingdom, Health Care, Medical Device


Company logo
Nextpharma

United Kingdom, Health Care, Pharmaceuticals

Market cap

39.0M $, 2026▼25.6% YoY

Revenue

19.0M $, 2024▼47.4% YoY

R&D intensity

10.53% 2024

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Market cap

39.0M $, 2026▼25.6% YoY

Revenue

19.0M $, FY2024▼47.4% YoY

EBITDA

-7.0M $, FY2024▼9.1% YoY

Operating margin

-76% Industry: -8722▲75.8% YoY

P/E ratio

-0.0 Industry: 6▲100% YoY

Revenue & EBITDA

$19.0MFY2024 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

-11.7M 2024▲123.5% YoY

Capex

1.0M 2024▼100% YoY

Debt/equity ratio

0.3 Industry: 2▼NaN% YoY

R&D intensity

10.5%FY2024

R&D as % of revenue

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Return on invested capital

-70.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

0.0

▼ 71.0%

2022

0.0

▼ 79.6%

2023

0.0

▼ 73.9%

2024

0.0

2025

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Not available

Recycling policy

Not available

Workplace health & safety policy

Not available

20%
Independent Directors

2 out of 10 incl. management

Powered by illuminem

Overall score

0

Environment

0

Social

0

Governance

0

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Not available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

Not committed to key sustainability initiatives

Sustainability employees


Total sustainability employees

1


    Available in
    Scale package

    Access
  • Email

  • Email